The quest to be recognised as a global leader in innovation led Biocon to discover and develop IN-105, oral insulin for diabetics. Faced with initial success, the Biocon team was rearing to charge ahead with the final testing. Everything looked rosy, but was it actually so? Nita Sachan, Senior Researcher, Biocon Cell for Innovation Management at the Centre for Leadership, Innovation and Change (CLIC), Prasad Kaipa, Senior Research Fellow & Director Emeritus, CLIC, Anand Nandkumar, Assistant Professor of Strategy, ISB and Charles Dhanaraj, Head & Senior Research Fellow, CLIC are co-authors of this case.
"It has been my dream to make a global impact with a “Made in India” label. I think a lot of my generation comes from that frame of reference. We have always had to apologise for India and now is the time we don’t want to apologise for our country. We want to be proud of it." - Kiran Mazumdar-Shaw
The morning of April 27, 2009 witnessed intense activity at Biocon’s Bangalore office, where the future of oral insulin IN-1051 was being discussed. As they completed their presentations to the committee, Harish Iyer, Head of R&D at Biocon, and Anand Khedkar, Senior Scientific Manager of the project, posed a tough question before Biocon’s senior management: How much risk was it ready to take with IN-105?